• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of miRNA-based immunotherapy in cancer

Research Project

Project/Area Number 18K07970
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53010:Gastroenterology-related
Research InstitutionOsaka University

Principal Investigator

Naohiro Nishida  大阪大学, 医学系研究科, 助教 (50588118)

Co-Investigator(Kenkyū-buntansha) 水島 恒和  大阪大学, 医学系研究科, 寄附講座教授 (00527707)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords大腸癌 / 免疫治療 / マイクロRNA / がん遺伝子 / 癌
Outline of Final Research Achievements

Immune escape is a key feature of cancer survival and progression. In our study, we aimed to identify microRNAs that plays a key role in inhibiting the tumor immunity and contribute to cancer progression. We successfully discovered microRNAs and genes that strongly overexpressed in cancer stromal tissues and confirmed that these molecules functions as crucial inhibitors of tumor immune system. Combinational use of inhibitors to these molecules and conventional immunotherapy could be a promising treatment strategy in colorectal cancer.

Academic Significance and Societal Importance of the Research Achievements

本研究では、腫瘍免疫に重要な役割を果たすマイクロRNAの同定と、その機能の解析を行った。大腸癌細胞株の実験と大規模オープンデータベースの解析から、間質においてがん免疫を抑制し、癌進展に関わるマイクロRNA、ならびに遺伝子候補群の同定に成功、これらが癌組織で高発現していることを確認した。現行の免疫チェックポイント阻害剤をはじめとする免疫治療に加えて、今回同定した分子を抑制することは、今後の大腸癌治療戦略において、重要な選択肢となり得る。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (6 results)

All 2020 2019 2018

All Journal Article (2 results) (of which Peer Reviewed: 2 results) Presentation (4 results)

  • [Journal Article] Involvement of MAF1 homolog, negative regulator of RNA polymerase III in colorectal cancer progression.2019

    • Author(s)
      Hokonohara K, Nishida N, Miyoshi N, Takahashi H, Haraguchi N, Hata T, Matsuda C, Mizushima T, Doki Y, Mori M.
    • Journal Title

      International Journal of Oncology

      Volume: 54 Pages: 1001-1009

    • Related Report
      2019 Research-status Report 2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Disruption of Endolysosomal RAB5/7 Efficiently Eliminates Colorectal Cancer Stem Cells.2019

    • Author(s)
      Takeda M, Koseki J, Takahashi H, Miyoshi N, Nishida N, Nishimura J, Hata T, Matsuda C, Mizushima T, Yamamoto H, Ishii H, Doki Y, Mori M, Haraguchi N.
    • Journal Title

      Cancer Res

      Volume: 79 Pages: 1426-1437

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Presentation] Identification of novel EMT regulators in colorectal cancer2020

    • Author(s)
      Naohiro Nishida, Satoshi Ishikawa, Daisuke Sakai, Toshifumi Yamaguchi, Shiki Fujino, Takayuki Ogino, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Tsunekazu Mizushima, Taroh Satoh, Masaki Mori, Hidetoshi Eguchi, Yuichiro Doki
    • Organizer
      日本癌学会
    • Related Report
      2020 Annual Research Report
  • [Presentation] BRAFV600E 変異陽性大腸癌に特異的な代謝機構の解明2020

    • Author(s)
      雪本 龍平、西田尚弘
    • Organizer
      日本外科学会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 新規上皮間葉転換関連遺伝子の同定とその大腸癌進展における意義の検討2020

    • Author(s)
      石川 慧、西田尚弘
    • Organizer
      日本外科学会
    • Related Report
      2020 Annual Research Report
  • [Presentation] Sequential expression of epithelial to mesenchymal transition related genes in cancer epithelium and stroma2018

    • Author(s)
      西田尚弘
    • Organizer
      日本癌学会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi